FMRP ‐Mediated Proteasome Regulation: A Novel Mechanism in ALS Pathology
The FASEB Journal · 2026
DOI: 10.1096/fj.202600563r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Pritha Majumder und 5 weiteren Autor:innen. Beteiligte Einrichtung: PhD Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Shuang-Ho Campus, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Proteasome Endopeptidase Complex, Fragile X Messenger Ribonucleoprotein 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council (NSTC).
Abstract (Originalsprache)
Amyotrophic Lateral Sclerosis (ALS) is a rare and fatal neurodegenerative disease characterized by the hallmark cytoplasmic accumulation and aggregation of TAR DNA binding protein 43 (TDP‐43), which impairs proteasome activity through its interaction with Tankyrase (TNKS). Using molecular and imaging techniques, we have identified a novel role for the Fragile X Mental Retardation Protein (FMRP) in regulating the TNKS/PI31‐mediated proteasome activation mechanism in co‐operation with TDP‐43. Our results demonstrate that depletion of FMRP causes nuclear translocation of TDP‐43, reducing cytoplasmic TNKS/TDP‐43 co‐localization, thereby releasing TNKS in the cytoplasm. Free TNKS gets associated with proteasome inhibitor of 31 kDa (PI31), reversing PI31‐mediated inhibition of proteasome assembly, trafficking, and activity. Thus, FMRP regulates proteasome activity by modulating the subcellular distribution of TDP‐43. Interestingly, FMRP expression is elevated in specific brain regions and spinal cords of TDP‐43 A315T transgenic ALS mice that helps more TDP‐43 to stay in cytoplasm to sequester more TNKS with it, resulting in proteasome dysfunction in ALS disease system. We have demonstrated for the first time that FMRP can act as a disease modifier for ALS. ALS patients with high FMRP expression in the brain and spinal cord may exhibit more severe protein aggregation due to proteasome dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PhD Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Shuang-Ho Campus, New Taipei City, Taiwan.
- Department of Biology, Georgetown University, Washington, DC, USA.
- International Master Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University, Shuang-Ho Campus, New Taipei City, Taiwan.
- School of Medicine, College of Medicine, Taipei Medical University, Shuang-Ho Campus, New Taipei City, Taiwan.
- TMU Research Center for Neuroscience, Taipei Medical University, Shuang-Ho Campus, New Taipei City, Taiwan.
ORCID-Profile: Pritha Majumder, Chi-Chen Sarah Huang
Förderung
- National Science and Technology Council (NSTC)
Zitieren
APA
Majumder, P., Ahsan, A., Bubphachat, P., Akter, K., Huang, J. K., & Huang, C. S. (2026). FMRP ‐Mediated Proteasome Regulation: A Novel Mechanism in ALS Pathology. The FASEB Journal. https://doi.org/10.1096/fj.202600563r
Vancouver
Majumder P, Ahsan A, Bubphachat P, Akter K, Huang JK, Huang CS. FMRP ‐Mediated Proteasome Regulation: A Novel Mechanism in ALS Pathology. The FASEB Journal. 2026. doi:10.1096/fj.202600563r
BibTeX
@article{Majumder2026,
author = {Majumder, Pritha and Ahsan, Asmar and Bubphachat, Pitchapa and Akter, Khadiza and Huang, Jeffrey K and Huang, Chi-Chen Sarah},
title = {FMRP ‐Mediated Proteasome Regulation: A Novel Mechanism in ALS Pathology},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202600563r}
}
EUVIMED